ABSTRACT
OBJECTIVE: To study the optimum parameters of the supercritical CO, fluid extraction of lotus leaves and chemical constituents of extractive matters. METHODS: Supercritical CO2 fluid extraction condition was selected by uniform design. The extraction pressure, extraction temperature, extraction time were three factors in the experiment. GC-MS was applied for analyzing the extraction. RESULTS: The optimum condition were obtained: the extraction pressure was 26 Mpa, the extraction temperature was 40 degrees C, the extracion time was 90 minutes. The major constituent was 1H-Pyrrole-2-carboxaldehyde, 1-ethyl-in extractive matters. CONCLUSION: Uniform design can optimize the CO2 Supercritical Fluid Extraction process quickly and accuratly with satisfactory results.
Subject(s)
Chromatography, Supercritical Fluid/methods , Drugs, Chinese Herbal/analysis , Gas Chromatography-Mass Spectrometry/methods , Lotus/chemistry , Plant Leaves/chemistry , Carbon Dioxide , Drugs, Chinese Herbal/isolation & purification , Fatty Acids/analysis , Fatty Acids/isolation & purification , Monoterpenes/analysis , Monoterpenes/isolation & purification , Plants, Medicinal/chemistry , Pressure , Reproducibility of Results , Technology, Pharmaceutical/methods , Temperature , Time FactorsABSTRACT
AIM: To explore the apoptotic effect of the combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel on p185-overexpressing human malignant breast cancer cell lines BT474 and to study its emerging mechanism. METHODS: The prohibitory effect of engineeded antibody plus paclitaxel on BT474 cells was assessed by MTS assay. The number of apoptotic cells was detected by Annexin V-FITC/PI. DNA content and cell cycle distribution were determined by FCM; DNA-binding activity of NF-kappaB was demonstrated by EMSA. RESULTS: Anti-p185(c-erbB-2/neu) engineered antibody plus paclitaxel resulted in synergistic effect on proliferative inhibiton of BT474 cells, which was mediated via apoptotic induction and caused cell cycle to arrest at G1 phase remarkably. Furthermore, the combined treatment of the engineered antibody with paclitaxel effectively suppressed the activation of NF-kappaB in BT474 cells. CONCLUSION: The combined treatment of anti-p185(c-erbB-2/neu) engineered antibody with paclitaxel rendered p185-overexpressing human malignant breast cancer cells BT474 more susceptible to paclitaxel-induced apoptosis by the effective suppression of NF-kappaB activation.
